Phaseline

Targets › BDKRB2

BDKRB2 (B2 bradykinin receptor): drug programs, companies and trials

1 program from 1 company in 7 trials: 3 Phase 4, 2 Phase 3, 2 Phase 2; Neurology, Cardiovascular, Gastroenterology; next expected readout Nov 2026.

Receptor for bradykinin. It is associated with G proteins that activate a phosphatidylinositol-calcium second messenger system. (UniProt, P30411)

Open in Phaseline: the race on BDKRB2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Vanderbilt University Medical Center[18F]MH.MZ
Bacterial penicillin-binding protein inhibitor
HTR2A, UNKNOWN, BDKRB2, Ion channelsPhase 4Neurodegenerative Diseases; Osteoarthritis, Knee; Pain; Intradialytic Hypotension …Nov 2026

Conditions

Neurodegenerative Diseases (1) Osteoarthritis, Knee (1) Pain (1) Intradialytic Hypotension (1) End Stage Renal Disease (1) Microtia (1) Acute Uncomplicated Diverticulitis (1)

Modalities

small molecule (1)

Companies

Vanderbilt University Medical Center (1)

Related targets

HTR2A (1) UNKNOWN (1) Ion channels (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.